secwatch.observer — SEC 8-K summary
======================================

Issuer:     PULSE BIOSCIENCES, INC. (PLSE)
CIK:        0001625101
Form:       8-K
Filed at:   2024-05-15T23:59:59+00:00
Accession:  0001437749-24-016821
Event type: leadership
Sentiment:  positive
Materiality: 0.60
Item codes: 5.02, 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Pulse Biosciences appoints Burke T. Barrett as CEO; Kevin Danahy becomes Chief Commercial Officer
--------------------------------------------------------------------------------

- Burke T. Barrett named President and CEO effective May 12, 2024; succeeds Kevin Danahy who becomes Chief Commercial Officer.
- Barrett previously CEO of CardioFocus, led global commercial launch of atrial fibrillation laser-balloon ablation device.
- Barrett receives options to purchase 1.4M shares at $7.45, half time-vested over 4 years, half upon $1B-$4B market cap milestones.
- Danahy and CTO Darrin Uecker amend employment agreements to reduce severance salary continuation from 12 to 3 months (12 months post-change of control).

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1625101/000143774924016821/0001437749-24-016821-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1625101/000143774924016821/plse20240513_8k.htm
  HTML page:      https://secwatch.observer/filing/0001437749-24-016821

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer